On July 27, 2021, Artios Pharma, a leading DNA Damage Response company, announced the completion of a US$153 million (£110 million) Series C financing to fund further development of its promising clinical-stage pipeline. The financing was co-led by Omega Funds and TCG X. Additional investors include Avidity Partners, Invus, Deep Track Capital, Sofinnova Partners, Tetragon Financial Group, RTW Investments, Soleus Capital, Piper Heartland Healthcare Capital, CaaS Capital Management, and Schroders Capital. These new investors join existing investors Arix Bioscience, SV Health Investors, Andera Partners, Life Sciences Partners, M Ventures, Pfizer Ventures, IP Group, and Novartis Venture Fund who also continue to support Artios through their participation. Wilson Sonsini Goodrich & Rosati represented RTW Investments in the transaction.
The funding round propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through deployment of Artios’ DDR-based platform and small molecule drug discovery capabilities.
Please see Artios’ press release for more information.